

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Mouse Anti-Chicken Vinculin Monoclonal Antibody, Unconjugated, Clone VIN-11-5

RRID:AB_477617

Type: Antibody

Proper Citation

Sigma-Aldrich Cat# V4505, RRID:AB_477617

Antibody Information

URL: http://antibodyregistry.org/AB_477617

Proper Citation: Sigma-Aldrich Cat# V4505, RRID:AB_477617

Target Antigen: Vinculin

Host Organism: mouse

Clonality: monoclonal

Comments: Vendor recommendations: Immunofluorescence; Western Blot; Indirect Immunofluorescence, Western Blot

Antibody Name: Mouse Anti-Chicken Vinculin Monoclonal Antibody, Unconjugated, Clone VIN-11-5

Description: This monoclonal targets Vinculin

Target Organism: chicken, chickenavian, mouse, bovine, human

Clone ID: Clone VIN-11-5

Antibody ID: AB_477617

Vendor: Sigma-Aldrich

Catalog Number: V4505

Record Creation Time: 20250819T232154+0000

Record Last Update: 20250820T050653+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Chicken Vinculin Monoclonal Antibody, Unconjugated, Clone VIN-11-5.

No alerts have been found for Mouse Anti-Chicken Vinculin Monoclonal Antibody, Unconjugated, Clone VIN-11-5.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 51 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fu Z, et al. (2026) Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. Cancer cell.

Song W, et al. (2025) Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. Cell reports, 44(10), 116433.

Ho-Xuan H, et al. (2025) YTHDF proteins and m6A-RNA clients undergo autophagic turnover during contact inhibition. Cell reports, 44(9), 116188.

Lei G, et al. (2025) Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Cancer cell, 43(6), 1076.

Lavanderos B, et al. (2025) Rhotekin-1 is a novel interacting protein and regulator of TRPC6 activity. The FEBS journal, 292(16), 4353.

Yu H, et al. (2025) Energy status orchestrates YTHDF1 phase separation and tumorigenesis. Cell reports, 44(11), 116466.

Cigrang M, et al. (2025) Pan-inhibition of super-enhancer-driven oncogenic transcription by next-generation synthetic ecteinascidins yields potent anti-cancer activity. Nature communications, 16(1), 512.

Madej M, et al. (2025) PUS10-induced tRNA fragmentation impacts retrotransposon-driven inflammation. Cell reports, 44(6), 115735.

Mao C, et al. (2024) Unraveling ETC complex I function in ferroptosis reveals a potential ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers. Molecular cell, 84(10), 1964.

Brock K, et al. (2024) A comparative analysis of paxillin and Hic-5 proximity interactomes. Cytoskeleton (Hoboken, N.J.).

Ryu JE, et al. (2024) Circadian regulation of endoplasmic reticulum calcium response in cultured mouse astrocytes. eLife, 13.

Hao M, et al. (2024) In vivo CRISPR knockout screen identifies p47 as a suppressor of HER2+ breast cancer metastasis by regulating NEMO trafficking and autophagy flux. *Cell reports*, 43(2), 113780.

Martin Flores N, et al. (2024) Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model. *eLife*, 12.

Tábara LC, et al. (2024) MTFP1 controls mitochondrial fusion to regulate inner membrane quality control and maintain mtDNA levels. *Cell*, 187(14), 3619.

Zhang D, et al. (2024) Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. *EBioMedicine*, 105, 105212.

Tam KJ, et al. (2024) Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. *Scientific reports*, 14(1), 7082.

He C, et al. (2024) UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. *Molecular cell*, 84(6), 1120.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. *Nature communications*, 14(1), 2859.

Chen M, et al. (2023) Identification of XAF1 as an endogenous AKT inhibitor. *Cell reports*, 42(7), 112690.

Jones ME, et al. (2023) A genetic variant of the Wnt receptor LRP6 accelerates synapse degeneration during aging and in Alzheimer's disease. *Science advances*, 9(2), eabo7421.